Literature DB >> 18318502

Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.

Joseph E Deweese1, Alex B Burgin, Neil Osheroff.   

Abstract

The ability to cleave DNA is critical to the cellular and pharmacological functions of human type II topoisomerases. However, the low level of cleavage at equilibrium and the tight coupling of the cleavage and ligation reactions make it difficult to characterize the mechanism by which these enzymes cut DNA. Therefore, to establish a system that isolates topoisomerase II-mediated DNA scission from ligation, oligonucleotide substrates were developed that contained a 3'-bridging phosphorothiolate at the scissile bond. Scission of these substrates generates a 3'-terminal -SH moiety that is a poor nucleophile relative to the normal 3'-terminal -OH group. Consequently, topoisomerase II cannot efficiently ligate phosphorothiolate substrates once they are cleaved. The characteristics of topoisomerase IIalpha-mediated cleavage of phosphorothiolate oligonucleotides were identical to those seen with wild-type substrates, except that no ligation was observed. This unidirectional accumulation of cleavage complexes provided critical information regarding coordination of the protomer subunits of topoisomerase IIalpha and the mechanism of action of topoisomerase II poisons. Results indicate that the two enzyme subunits are partially coordinated and that cleavage at one scissile bond increases the degree of cleavage at the other. Furthermore, anticancer drugs such as etoposide and amsacrine that strongly inhibit topoisomerase II-mediated DNA ligation have little effect on the forward scission reaction. In contrast, abasic sites that increase levels of cleavage complexes without affecting ligation stimulate the forward rate of scission. Phosphorothiolate substrates provide significant advantages over traditional "suicide substrates" and should be valuable for future studies on DNA scission and the topoisomerase II-DNA cleavage complex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318502      PMCID: PMC2733888          DOI: 10.1021/bi702194x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  80 in total

1.  Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells.

Authors:  Renier Vélez-Cruz; James N Riggins; J Scott Daniels; Hongliang Cai; F Peter Guengerich; Lawrence J Marnett; Neil Osheroff
Journal:  Biochemistry       Date:  2005-03-15       Impact factor: 3.162

Review 2.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

Review 3.  Interfacial inhibitors of protein-nucleic acid interactions.

Authors:  Yves Pommier; Christophe Marchand
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-07

Review 4.  Topoisomerase II inhibitors.

Authors:  Danko Martincic; Kenneth R Hande
Journal:  Cancer Chemother Biol Response Modif       Date:  2005

5.  Single-molecule measurements of the opening and closing of the DNA gate by eukaryotic topoisomerase II.

Authors:  R Derike Smiley; Tammy R L Collins; Gordon G Hammes; Tao-Shih Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

6.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Authors:  Christophe Marchand; Smitha Antony; Kurt W Kohn; Mark Cushman; Alexandra Ioanoviciu; Bart L Staker; Alex B Burgin; Lance Stewart; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

7.  Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Authors:  Bart L Staker; Michael D Feese; Mark Cushman; Yves Pommier; David Zembower; Lance Stewart; Alex B Burgin
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

Review 8.  Topoisomerase II and the etiology of chromosomal translocations.

Authors:  Carolyn A Felix; Christos P Kolaris; Neil Osheroff
Journal:  DNA Repair (Amst)       Date:  2006-07-20

Review 9.  Etoposide, topoisomerase II and cancer.

Authors:  E L Baldwin; N Osheroff
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-07

Review 10.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

View more
  27 in total

1.  Sin resolvase catalytic activity and oligomerization state are tightly coupled.

Authors:  Kent W Mouw; Andrew M Steiner; Rodolfo Ghirlando; Nan-Sheng Li; Sally-J Rowland; Martin R Boocock; W Marshall Stark; Joseph A Piccirilli; Phoebe A Rice
Journal:  J Mol Biol       Date:  2010-09-22       Impact factor: 5.469

2.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

3.  Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavage.

Authors:  Ross A Keenholtz; Kent W Mouw; Martin R Boocock; Nan-Sheng Li; Joseph A Piccirilli; Phoebe A Rice
Journal:  J Biol Chem       Date:  2013-08-22       Impact factor: 5.157

Review 4.  Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Authors:  Yves Pommier; Shar-yin N Huang; Rui Gao; Benu Brata Das; Junko Murai; Christophe Marchand
Journal:  DNA Repair (Amst)       Date:  2014-05-22

5.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

6.  Selection of DNA Cleavage Sites by Topoisomerase II Results from Enzyme-Induced Flexibility of DNA.

Authors:  Yunsu Jang; Heyjin Son; Sang-Wook Lee; Wonseok Hwang; Seung-Ryoung Jung; Jo Ann W Byl; Neil Osheroff; Sanghwa Lee
Journal:  Cell Chem Biol       Date:  2019-01-31       Impact factor: 8.116

7.  The DNA-gate of Bacillus subtilis gyrase is predominantly in the closed conformation during the DNA supercoiling reaction.

Authors:  Airat Gubaev; Manuel Hilbert; Dagmar Klostermeier
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-29       Impact factor: 11.205

8.  Recovery of the poisoned topoisomerase II for DNA religation: coordinated motion of the cleavage core revealed with the microsecond atomistic simulation.

Authors:  Nan-Lan Huang; Jung-Hsin Lin
Journal:  Nucleic Acids Res       Date:  2015-07-06       Impact factor: 16.971

9.  A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases.

Authors:  Bryan H Schmidt; Alex B Burgin; Joseph E Deweese; Neil Osheroff; James M Berger
Journal:  Nature       Date:  2010-06-03       Impact factor: 49.962

10.  Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.

Authors:  Joseph E Deweese; F Peter Guengerich; Alex B Burgin; Neil Osheroff
Journal:  Biochemistry       Date:  2009-09-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.